Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.85 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.85 |
| ▸ | ADRB3 known ✓ | P13945 | 6/20 | 0.82 |
| ▸ | MAPT | P10636 | 7/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | BLM | P54132 | 6/20 | 0.85 |
| ▸ | TSHR | P16473 | 4/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.85 |
| ▸ | POLB | P06746 | 3/20 | 0.85 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.85 |
| ▸ | GAA | P10253 | 2/20 | 0.85 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.85 |
| ▸ | MEN1 | O00255 | 6/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.82 |
| ▸ | LMNA | P02545 | 5/20 | 0.82 |
| ▸ | MTOR | P42345 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL7268328 | 0.98 | ADRB2 (0.85) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL41841 | 0.95 | MAPT (0.85) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL5682034 | 0.94 | MAPT (0.82) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL9614622 | 0.92 | MAPT (1.00) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL28872988 | 0.92 | MAPT (1.00) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Levisoprenaline SCHEMBL4745572 | 0.92 | MAPT (1.00) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL7627 | 0.92 | MAPT (1.00) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL3672791 | 0.92 | MAPT (1.00) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Levisoprenaline SCHEMBL250806 | 0.91 | MAPT (1.00) | ADRB2MAPTKDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL3253794 | 0.91 | MAPT (1.00) | ADRB2MAPTKDM4ETDP1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042561-B2 | Hydrophobic molecule-induced branched polymer aggregates and their use | ANP TECHNOLOGIES, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240016754-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TAXANE NANOAGGREGATES AND USE THEREOF | FULGENT GENETICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023178038-A1 | NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF | FULGENT GENETICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023177629-A1 | POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF | ANP TECHNOLOGIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-114466658-A | Orally delivered therapeutic compositions and uses thereof | 沈海发 | 2022-05-10 | — | — | CN | disclosed |
| EP-3925625-A1 | HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE | ANP Technologies, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021046497-A2 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | SHEN HAIFA (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-2661281-B1 | HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE | ANP TECH INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210059939-A1 | Hydrophobic Molecule-Induced Branched Polymer Aggregates and their Use | FULGENT GENETICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200392289-A1 | Biodegradable Polymer and Use Thereof | FULGENT GENETICS, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-1999040787-A1 | MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040907-A1 | METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5916910-A | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore | MEDINOX, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5916596-A | WATER INSOLUBLE DRUGS AND DRUG DELIVERY | VIVORX PHARMACEUTICALS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1999000113-A9 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS INC (US) | 1999-04-08 | — | — | WO | disclosed |
| US-5875776-A | Dry powder inhaler | VIVORX PHARMACEUTICALS, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1999000113-A1 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998055453-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998014174-A1 | PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997037708-A1 | DRY POWDER INHALER | VIVORX PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392289-A1 | Biodegradable Polymer and Use Thereof | PBK, PUF60, CD47 | ADRB2 4746/4885ADRB1 4626/4885ADRB3 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.